Podcast episode 11 (in German)
Semax – Russian nootropic fact-checked
July 4, 2026
A few drops in the nose, and the head feels clearer: that is how many users describe Semax. Behind the peptide from Russian research is a growth factor that is something like fertilizer for nerve cells.
What it is about
Semax is a small synthetic peptide of 7 building blocks, developed at the Institute of Molecular Genetics in Russia. It is derived from a fragment of the hormone ACTH, but without its hormonal effect; an attached end piece protects it from rapid breakdown. Its best-known effect: it raises BDNF and NGF, growth factors that let nerve cells grow, network and survive. The episode explains how this relates to focus and mood, how Semax is used in Russia for stroke and where it fits alongside caffeine and modafinil. At the end stands one of the gentler nootropic peptides with a real clinical history, whose research, however, comes predominantly from one country.
Key points
- Semax consists of 7 building blocks of an ACTH fragment; the part chosen deliberately is the one that influences attention and memory in the brain without flooding the body with stress hormones.
- A 2002 paper by Kaplan and colleagues describes that Semax increased the activity of the neurotrophic factors BDNF and NGF in the brain.
- In a 2011 study by Gusev and colleagues, Semax improved recovery in patients with ischemic stroke; in Russia it is an approved medicine.
- As a report: users describe clear focus and mental energy without the jitteriness of caffeine, often within minutes to just under half an hour after nasal use.
- Semax is not a stimulant in the classic sense and does not push the heart; it acts via growth factors and additionally influences messengers such as dopamine and serotonin.
- Alongside classic Semax there is the stronger, longer-acting N-acetyl Semax; a popular combination is with the calming peptide Selank from the same Russian research tradition.
- The side effect most likely mentioned is mild irritation of the nose; systemic problems are rarely described after decades of use in Russia.
Where the data stop
Most of the research comes from Russia and is less known internationally and less often independently replicated. Clinical practice there does not replace a broad body of studies, and the effects on focus and mood in healthy people rest mainly on user reports. The friendly safety profile, too, draws on long use in one country, not on large international studies.
Outside Russia, Semax is not approved as a medicine, as of July 2026. In the biohacking scene it comes as a research peptide from the gray market, where quality and origin are not guaranteed. Anyone considering Semax is best advised to discuss it with someone knowledgeable.
Listen (in German)
Listen on Spotify Listen on Apple Podcasts Listen on Amazon Music
Published on July 4, 2026.
The topic in the database
- A nootropic peptide developed in Russia that raises BDNF/NGF and is being studied for neuroprotection – applied intranasally, but without systematicSemax
All episodes in the app (German)
Information only, not medical advice and not a usage or dosage recommendation. Prescription-only and unapproved substances belong in the hands of a physician. Last updated: 2026-10-09.